Esperion Secures Patent Protection for NEXLETOL Until 2040 Through Settlement with Micro Labs
• Esperion Therapeutics has reached a settlement agreement with Micro Labs that prevents the generic manufacturer from marketing a version of NEXLETOL (bempedoic acid) before April 19, 2040.
• The agreement resolves patent litigation initiated by Esperion in response to Micro Labs' Abbreviated New Drug Application seeking approval for a generic version of the cholesterol-lowering medication.
• Litigation against eight other ANDA filers continues, with no guarantee that these ongoing cases will prevent other generic versions from entering the market before the 2040 patent expiration.
© Copyright 2025. All Rights Reserved by MedPath